Lercanidipine Accord

Lercanidipine, the active ingredient in Lercanidipine Accord, is a calcium channel blocker presented as an oral tablet for oral administration. It selectively inhibits L‑type calcium channels in vascular smooth muscle, producing arterial vasodilation and lowering peripheral resistance. The medication is used to treat hypertension in adult patients.

GNH USA supplies Lercanidipine Accord as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. Our distribution network provides quality‑assured products that meet EU regulatory standards and support global healthcare procurement.

Lercanidipine is a calcium channel blocker used to manage high blood pressure.

- Hypertension: lowers elevated systolic and diastolic blood pressure. - Essential hypertension: provides long‑term control of primary high blood pressure. - Isolated systolic hypertension: helps reduce high systolic pressure in older adults.

Lercanidipine may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects: - Headache: mild to moderate pain often occurring after dose initiation. - Flushing: transient warmth and redness of the skin. - Peripheral edema: swelling of the ankles or lower limbs. - Dizziness: sensation of light‑headedness, especially when standing quickly. - Nausea: mild gastrointestinal upset. - Tachycardia: increased heart rate, usually mild.

Serious or Rare Side Effects: - Severe hypotension: marked drop in blood pressure that may cause fainting. - Myocardial infarction: rare occurrence of heart attack. - Hepatic dysfunction: abnormal liver enzyme elevations. - Allergic reactions: including angioedema, rash, or urticaria. - Arrhythmias: irregular heart rhythms, including heart block. - Heart failure exacerbation: worsening of existing cardiac failure.

When prescribing Lercanidipine, clinicians should consider several safety measures.

- Dose adjustment: required in hepatic impairment. - Monitor blood pressure: avoid excessive hypotension, especially after dose changes. - Caution in elderly: increased risk of peripheral edema and dizziness. - Avoid concomitant use with strong CYP3A4 inhibitors: may increase drug exposure. - Pregnancy and lactation: safety not established; use only if benefit outweighs risk. - Store at ambient temperature: keep in original container, protect from moisture and light.

Lercanidipine can interact with other medicines, affecting its efficacy or safety.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may raise plasma levels. - Grapefruit juice: can increase drug concentration and risk of hypotension. - Other antihypertensives (e.g., ACE inhibitors, diuretics): additive blood‑pressure lowering effect.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce effectiveness. - Beta‑blockers: combined use may enhance bradycardia or AV‑block risk.